Boxer Capital, LLC Buys AveXis, BeiGene, Alnylam Pharmaceuticals, Sells Biomarin Pharmaceutical, Seattle Genetics, Rigel Pharmaceuticals

• New Purchases: ALNY, ALXN, SBBP, SNSS, BLPH, RXDX,
• Added Positions: AVXS, BGNE, MDCO,
• Reduced Positions: SGEN, CLVS, ARDM,
• Sold Out: BMRN, RIGL, HRTX, EBIO, EPIX,

For the details of Boxer Capital, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Boxer+Capital%2C+LLC

1. AveXis Inc (AVXS) - 1,028,763 shares, 20.71% of the total portfolio. Shares added by 243.20%
2. Clovis Oncology Inc (CLVS) - 850,000 shares, 15.93% of the total portfolio. Shares reduced by 15%
3. The Medicines Co (MDCO) - 828,198 shares, 11.86% of the total portfolio. Shares added by 18.31%
4. BeiGene Ltd (BGNE) - 850,000 shares, 10.88% of the total portfolio. Shares added by 72.19%
5. Blueprint Medicines Corp (BPMC) - 705,159 shares, 8.34% of the total portfolio.

Boxer Capital, LLC initiated holdings in Alnylam Pharmaceuticals Inc. The purchase prices were between $31.41 and $70.3, with an estimated average price of $41.87. The stock is now traded at around $47.02. The impact to the portfolio due to this purchase was 3.95%. The holdings were 250,000 shares as of 2016-12-31.

Boxer Capital, LLC initiated holdings in Alexion Pharmaceuticals Inc. The purchase prices were between $110.01 and $135.59, with an estimated average price of $122.36. The stock is now traded at around $130.39. The impact to the portfolio due to this purchase was 3.87%. The holdings were 75,000 shares as of 2016-12-31.

Boxer Capital, LLC initiated holdings in Strongbridge Biopharma PLC. The purchase prices were between $2.3 and $5.4, with an estimated average price of $4.08. The stock is now traded at around $2.45. The impact to the portfolio due to this purchase was 0.95%. The holdings were 940,000 shares as of 2016-12-31.

Boxer Capital, LLC initiated holdings in Sunesis Pharmaceuticals Inc. The purchase prices were between $3.49 and $4.71, with an estimated average price of $3.98. The stock is now traded at around $4.10. The impact to the portfolio due to this purchase was 0.8%. The holdings were 525,000 shares as of 2016-12-31.

Boxer Capital, LLC initiated holdings in Bellerophon Therapeutics Inc. The purchase prices were between $0.47 and $1.48, with an estimated average price of $0.93. The stock is now traded at around $0.91. The impact to the portfolio due to this purchase was 0.41%. The holdings were 1,857,143 shares as of 2016-12-31.

Boxer Capital, LLC initiated holdings in Ignyta Inc. The purchase prices were between $4.25 and $7.1, with an estimated average price of $5.83. The stock is now traded at around $9.55. The impact to the portfolio due to this purchase was 0.28%. The holdings were 125,000 shares as of 2016-12-31.

Boxer Capital, LLC added to the holdings in AveXis Inc by 243.20%. The purchase prices were between $42 and $71.36, with an estimated average price of $53.44. The stock is now traded at around $59.36. The impact to the portfolio due to this purchase was 14.68%. The holdings were 1,028,763 shares as of 2016-12-31.

Boxer Capital, LLC added to the holdings in BeiGene Ltd by 72.19%. The purchase prices were between $26.95 and $36.9, with an estimated average price of $31.43. The stock is now traded at around $40.78. The impact to the portfolio due to this purchase was 4.56%. The holdings were 850,000 shares as of 2016-12-31.

Boxer Capital, LLC sold out the holdings in Biomarin Pharmaceutical Inc. The sale prices were between $78.62 and $95.92, with an estimated average price of $86.

Boxer Capital, LLC sold out the holdings in Rigel Pharmaceuticals Inc. The sale prices were between $2.38 and $4.01, with an estimated average price of $2.86.

Boxer Capital, LLC sold out the holdings in Heron Therapeutics Inc. The sale prices were between $12.4 and $20.35, with an estimated average price of $15.69.

Boxer Capital, LLC sold out the holdings in Eleven Biotherapeutics Inc. The sale prices were between $1.41 and $2.92, with an estimated average price of $2.2.

Boxer Capital, LLC sold out the holdings in ESSA Pharma Inc. The sale prices were between $1.8 and $2.73, with an estimated average price of $2.18.